azasetron

Subscribe to Selected New Research on azasetron

20 relevant articles (4 outcomes, 1 trials/studies) found for this Bio-Agent

Description: a selective 5-HT3 receptor antagonist; structure given in first source;

Also Known As:

N-(1-azabicyclo(2.2.2)oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4 -dihydro-2H-1,4-benzoxazine-8-carboxamide hydrochloride; Y 25130; Y-25130; azasetron, (+-)-isomer; 2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Konaka, Masako: 1 article (05/2006)
2.	Sato, Hideki: 1 article (05/2006)
3.	Totsu, Sawako: 1 article (05/2006)
4.	Inotsume, Nobuo: 1 article (05/2006)
5.	Hayakawa, Toru: 1 article (05/2006)
6.	Fujita, Akihisa: 1 article (05/2006)
7.	Makino, Azusa: 1 article (05/2006)
8.	Sato, Mayumi: 1 article (05/2006)
9.	Sekine, Kyu-ichiro: 1 article (05/2006)
10.	Hirohata, Tae: 1 article (05/2006)

Related Diseases

1.	Vomiting 11/01/1993 - "The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis." 04/24/1991 - "From these results, it is suggested that Y-25130 may become an effective antiemetic drug against emesis induced by anticancer therapy." 04/24/1991 - "Y-25130, at the dose of 0.3 mg/kg i.v., almost completely inhibited X-radiation-induced emesis in ferrets" 03/01/1996 - "From these data, continuous intravenous infusion of azasetron was considered to be highly effective in prophylaxis of nausea and vomiting induced by anticancer drugs." 03/01/1996 - "Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]" Get all the results and reference details, order at left...
2.	Nausea 03/01/1996 - "From these data, continuous intravenous infusion of azasetron was considered to be highly effective in prophylaxis of nausea and vomiting induced by anticancer drugs." 03/01/1996 - "Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]" 05/01/1997 - "Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]" 05/01/2006 - "However, the grade of nausea was significantly lower in the ramosetron group than in the azasetron group" 06/01/1997 - "Consequently, the suppository form of azasetron hydrochloride may be feasible for the treatment of chemotherapy-induced acute emesis and nausea." Get all the results and reference details, order at left...
3.	Bradycardia 10/01/1991 - "Atropine inhibited the bradycardia caused by electrical stimulation of the vagus nerve, but Y-25130 had no inhibitory effect" 04/01/2002 - "4. Although some of the effects described above resembled those of 5-HT (25 microg kg(-1)), the bradycardia and hypotensive actions of the latter were abolished by the 5HT(3)-receptor antagonist, azasetron, whereas those of anandamide were generally unaffected" 05/01/1999 - "The inhibitory effect of KB-R6933 at a dose of 0.3 microg/kg lasted for at least 8 hr, whereas those of granisetron at 30 microg/kg, ondansetron at 100 microg/kg and azasetron at 30 microg/kg nearly disappeared within 2-4 hr. Oral administration of KB-R6933 and granisetron also inhibited the bradycardia, with ED50 values of 0.41 and 76.3 microg/kg, respectively" 05/01/1999 - "Intravenous administration of KB-R6933, granisetron, ondansetron and azasetron inhibited 5-HT-induced bradycardia (von Bezold-Jarisch reflex) in anesthetized rats, with ED50 values of 0.071, 0.71, 4.0 and 0.82 microg/kg, respectively" Get all the results and reference details, order at left...
4.	Neoplasms (Cancer) 10/01/1997 - "Furthermore, the multidrug-resistant cancer cell line K562/ADM that overexpresses P-glycoprotein accumulated azasetron less extensively than did the parental drug-sensitive K562 cells" 05/01/2003 - "Twenty-one consecutive patients with advanced metastatic gastric cancer and performance status of 0-2, who had received prior chemotherapy with S-1, but had nonetheless shown unrelenting tumor progression, were treated with 60 mg/m(2) of I combined with 6 mg/m(2) of P, administered by intravenous infusion over 90 min following premedication with azasetron (I/low-P)" Get all the results and reference details, order at left...
5.	Carcinoma (Carcinomatosis) 09/01/2000 - "A randomized crossover study between azasetron alone and azasetron combined with dexamethasone was performed to investigate the prevention of nausea and vomiting due to chemotherapy including cisplatin in patients with advanced head and neck carcinoma" 11/01/1995 - "In freshly advanced head and neck carcinoma cases, a randomised crossover study was performed to compare the efficacy and safety profile of a single intravenous dose for 7 days of azasetron (10 mg/day) or granisetron (3 mg/day) in the prophylaxis of nausea and vomiting induced by multi-drug chemotherapy including cisplatin (50 mg/m2 or 60 mg/m2)" Get all the results and reference details, order at left...
15 Diseases and 20 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
2.	Cisplatin (Platino)
3.	Granisetron (Kytril)
4.	Dexamethasone (Maxidex)
5.	Ondansetron (Zofran)
6.	Serotonin (5 Hydroxytryptamine)
7.	ramosetron (Nasea)
8.	P-Glycoprotein
9.	Metoclopramide (Reglan)
10.	Ketanserin
18 Drugs and Important Bio-Agents and 17 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Premedication
2 Therapies and Procedures and 8 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>